10/12/2026
A new option for Parkinson's disease.
The FDA approved tavapadon (brand name Juvmo) for adults with Parkinson's disease. We asked Dr. Aaron Ellenbogen, medical director of MIND's Parkinson's Disease & Movement Disorders Center and a fellowship-trained movement disorders neurologist, what patients and families should know:
“Tavapadon is a new kind of Parkinson's medication. Like other drugs in its class (called dopamine agonists), it works by acting on the brain's dopamine system — the signaling that Parkinson's disease damages and that controls movement. What makes tavapadon different is that it's more selective: it switches on one specific set of dopamine receptors (called D1/D5) that drive movement, while largely leaving alone another set (D2/D3) that earlier medications stimulated. Because those D2/D3 receptors are tied to some of the troublesome side effects we've seen with older drugs in this class — such as sudden sleepiness and impulse-control problems like compulsive gambling or shopping — targeting movement more precisely may ease Parkinson's symptoms with less of that risk. It's taken as one pill once a day.
“Tavapadon may help people across the range of Parkinson's disease: those in earlier stages, and those with more advanced disease whose symptoms come and go between doses of their current medication (levodopa)."
Parkinson's disease is a progressive neurological disorder affecting millions of people worldwide.
If you or someone you love is living with Parkinson's, talk with your MIND neurologist about whether tavapadon could be part of your care.
Read more here: https://bit.ly/3W5N1CB